US7674396B2 - Method and system for treatment of eating disorders - Google Patents
Method and system for treatment of eating disorders Download PDFInfo
- Publication number
- US7674396B2 US7674396B2 US11/270,397 US27039705A US7674396B2 US 7674396 B2 US7674396 B2 US 7674396B2 US 27039705 A US27039705 A US 27039705A US 7674396 B2 US7674396 B2 US 7674396B2
- Authority
- US
- United States
- Prior art keywords
- gastric device
- subject
- volume
- core material
- outer region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 238000000034 method Methods 0.000 title abstract description 15
- 238000011282 treatment Methods 0.000 title description 9
- 208000030814 Eating disease Diseases 0.000 title description 7
- 208000019454 Feeding and Eating disease Diseases 0.000 title description 7
- 235000014632 disordered eating Nutrition 0.000 title description 6
- 230000002496 gastric effect Effects 0.000 claims abstract description 317
- 239000000463 material Substances 0.000 claims abstract description 140
- 210000002784 stomach Anatomy 0.000 claims abstract description 99
- 235000013305 food Nutrition 0.000 claims abstract description 81
- 239000011162 core material Substances 0.000 claims description 97
- 230000036571 hydration Effects 0.000 claims description 62
- 238000006703 hydration reaction Methods 0.000 claims description 62
- 229920001817 Agar Polymers 0.000 claims description 43
- 210000001198 duodenum Anatomy 0.000 claims description 43
- -1 poly(L-lactide) Polymers 0.000 claims description 42
- 239000006260 foam Substances 0.000 claims description 41
- 239000008272 agar Substances 0.000 claims description 36
- 235000010419 agar Nutrition 0.000 claims description 36
- 230000037406 food intake Effects 0.000 claims description 35
- 239000002253 acid Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 239000000499 gel Substances 0.000 claims description 23
- 239000012783 reinforcing fiber Substances 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 21
- 235000010418 carrageenan Nutrition 0.000 claims description 20
- 229920001525 carrageenan Polymers 0.000 claims description 20
- 239000000679 carrageenan Substances 0.000 claims description 20
- 229940113118 carrageenan Drugs 0.000 claims description 20
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229920001285 xanthan gum Polymers 0.000 claims description 12
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 11
- 229920002148 Gellan gum Polymers 0.000 claims description 11
- 229920001615 Tragacanth Polymers 0.000 claims description 11
- 229920001277 pectin Polymers 0.000 claims description 11
- 235000010987 pectin Nutrition 0.000 claims description 11
- 239000001814 pectin Substances 0.000 claims description 11
- 244000215068 Acacia senegal Species 0.000 claims description 10
- 241000416162 Astragalus gummifer Species 0.000 claims description 10
- 229920002907 Guar gum Polymers 0.000 claims description 10
- 229920000084 Gum arabic Polymers 0.000 claims description 10
- 235000015125 Sterculia urens Nutrition 0.000 claims description 10
- 240000001058 Sterculia urens Species 0.000 claims description 10
- 235000010489 acacia gum Nutrition 0.000 claims description 10
- 239000000205 acacia gum Substances 0.000 claims description 10
- 239000000835 fiber Substances 0.000 claims description 10
- 235000010417 guar gum Nutrition 0.000 claims description 10
- 239000000665 guar gum Substances 0.000 claims description 10
- 229960002154 guar gum Drugs 0.000 claims description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
- 229920003043 Cellulose fiber Polymers 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 7
- 108010000912 Egg Proteins Proteins 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 210000004211 gastric acid Anatomy 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims description 3
- 241000609240 Ambelania acida Species 0.000 claims description 3
- 240000006248 Broussonetia kazinoki Species 0.000 claims description 3
- 235000006716 Broussonetia kazinoki Nutrition 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 3
- 240000000491 Corchorus aestuans Species 0.000 claims description 3
- 235000011777 Corchorus aestuans Nutrition 0.000 claims description 3
- 235000010862 Corchorus capsularis Nutrition 0.000 claims description 3
- 240000000797 Hibiscus cannabinus Species 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 240000006240 Linum usitatissimum Species 0.000 claims description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 3
- 229920003091 Methocel™ Polymers 0.000 claims description 3
- 241000209504 Poaceae Species 0.000 claims description 3
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 3
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 239000010905 bagasse Substances 0.000 claims description 3
- 235000009120 camo Nutrition 0.000 claims description 3
- 235000005607 chanvre indien Nutrition 0.000 claims description 3
- 239000011487 hemp Substances 0.000 claims description 3
- 229920005610 lignin Polymers 0.000 claims description 3
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 3
- 229920000117 poly(dioxanone) Polymers 0.000 claims description 3
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920002643 polyglutamic acid Polymers 0.000 claims description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims 17
- 150000004676 glycans Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 abstract description 7
- 230000001079 digestive effect Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 239000007789 gas Substances 0.000 description 46
- 239000010410 layer Substances 0.000 description 42
- 235000010443 alginic acid Nutrition 0.000 description 29
- 229920000615 alginic acid Polymers 0.000 description 29
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 21
- 229940072056 alginate Drugs 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 239000002585 base Substances 0.000 description 15
- 229920000161 Locust bean gum Polymers 0.000 description 14
- 235000010420 locust bean gum Nutrition 0.000 description 14
- 208000008589 Obesity Diseases 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 235000020824 obesity Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 150000004781 alginic acids Chemical class 0.000 description 8
- 235000019789 appetite Nutrition 0.000 description 8
- 230000036528 appetite Effects 0.000 description 8
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 7
- 229920000945 Amylopectin Polymers 0.000 description 7
- 244000106483 Anogeissus latifolia Species 0.000 description 7
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 7
- 229920001287 Chondroitin sulfate Polymers 0.000 description 7
- 241001428166 Eucheuma Species 0.000 description 7
- 229920000855 Fucoidan Polymers 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 239000001922 Gum ghatti Substances 0.000 description 7
- 229920000569 Gum karaya Polymers 0.000 description 7
- 241001428259 Hypnea Species 0.000 description 7
- 229920001543 Laminarin Polymers 0.000 description 7
- 239000000783 alginic acid Substances 0.000 description 7
- 229960001126 alginic acid Drugs 0.000 description 7
- 239000004566 building material Substances 0.000 description 7
- 229940059329 chondroitin sulfate Drugs 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 235000019314 gum ghatti Nutrition 0.000 description 7
- 235000010494 karaya gum Nutrition 0.000 description 7
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 7
- 239000000711 locust bean gum Substances 0.000 description 7
- 229920001206 natural gum Polymers 0.000 description 7
- 229920001308 poly(aminoacid) Polymers 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 235000010487 tragacanth Nutrition 0.000 description 7
- 239000000196 tragacanth Substances 0.000 description 7
- 229940116362 tragacanth Drugs 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 210000003736 gastrointestinal content Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 210000005070 sphincter Anatomy 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 235000005686 eating Nutrition 0.000 description 4
- 230000007937 eating Effects 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 235000019525 fullness Nutrition 0.000 description 4
- 229920000591 gum Polymers 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 230000000153 supplemental effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 239000013585 weight reducing agent Substances 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002830 appetite depressant Substances 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 2
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- 235000003421 Plantago ovata Nutrition 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000009223 Psyllium Substances 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 208000012696 congenital leptin deficiency Diseases 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000004872 foam stabilizing agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 231100000508 hormonal effect Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229940070687 psyllium Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 239000003488 releasing hormone Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 208000033054 Cushing disease Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 230000009543 pathological alteration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/044—Oesophagi or esophagi or gullets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Definitions
- FIG. 5B is a plan, sectional view of the gastric device shown in FIG. 5A after hydration and expansion, according to the invention.
- FIGS. 6 and 7 are schematic illustrations of oblong and spherical shaped gastric devices, according to the invention.
- FIG. 9B is a perspective, sectional view of the gastric device shown in FIG. 9A after hydration and expansion, according to the invention.
- foams of the invention can be obtained by blowing, beating, shaking, spraying or stirring a solution of polymer in the presence of the desired gas, such as air, while the gel is being formed.
- Natural or synthetic foam stabilizing agents can also be added, such as protein, egg white, or detergents, such as SDS.
- the present invention substantially reduces or eliminates the disadvantages and shortcomings associated with prior art gastric devices.
- the invention generally comprises a gastric device that expands sufficiently in the stomach of a subject to at least partially suppress the subject's appetite.
- a key advantage of the gastric devices of the invention is the provision of a safe and efficient means of limiting food and, hence, caloric intake to facilitate weight reduction.
- the gastric devices are also readily adaptable to meet the needs of virtually any subject.
- the materials (discussed below) and thickness of the outer region 22 (see, e.g., FIGS. 3B and 4 ) of the outer region 22 can also be selected to achieve a desired degradation or, alternatively, passage and/or degradation rate(s) and, hence, desired residence time (e.g., 2, 6, 9, 12 or 24 hours or more) in the stomach.
- desired residence time e.g. 2, 6, 9, 12 or 24 hours or more
- the gastric device and/or device material simply passes into the intestines and through as a human fecal waste product.
- the gastric devices 20 A, 20 D include a base and an acid.
- Suitable bases include, without limitation, sodium bicarbonate, sodium carbonate, hydrogen carbonates or carbonates of alkali metals or organic cations, such as ammonium derivatives and sodium azide, and combinations and mixtures thereof.
- the member 56 can be formed (or processed) using various conventional processing methods.
- the member 56 is made from a solution of hot agar that is allowed to gel in a desired shape.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (17)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/270,397 US7674396B2 (en) | 2005-11-08 | 2005-11-08 | Method and system for treatment of eating disorders |
| US12/930,377 US20110112383A1 (en) | 2005-11-08 | 2011-01-04 | Devices, systems and methods for treatment of eating disorders |
| US13/875,086 US20130245663A1 (en) | 2005-11-08 | 2013-05-01 | Devices, Systems and Methods for Treatment of Eating Disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/270,397 US7674396B2 (en) | 2005-11-08 | 2005-11-08 | Method and system for treatment of eating disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/270,273 Continuation US7686892B2 (en) | 2004-11-19 | 2005-11-09 | Whiteness perception compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20070104754A1 US20070104754A1 (en) | 2007-05-10 |
| US7674396B2 true US7674396B2 (en) | 2010-03-09 |
Family
ID=38004007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/270,397 Expired - Fee Related US7674396B2 (en) | 2005-11-08 | 2005-11-08 | Method and system for treatment of eating disorders |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US7674396B2 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150150701A1 (en) * | 2012-06-07 | 2015-06-04 | Tulip Medical Ltd. | Expanded device |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US20170172778A1 (en) * | 2015-12-16 | 2017-06-22 | Obalon Therapeutics, Inc. | Intragastric device with expandable portions |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10413436B2 (en) | 2010-06-13 | 2019-09-17 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10463520B2 (en) | 2011-01-21 | 2019-11-05 | Obalon Therapeutics, Inc. | Intragastric device |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10874537B2 (en) | 2008-10-16 | 2020-12-29 | Obalon Therapeutics, Inc. | Intragastric volume-occupying device and method for fabricating same |
| US11129793B2 (en) | 2013-12-05 | 2021-09-28 | Epitomee Medical Ltd | Retentive devices and systems for in-situ release of pharmaceutical active agents |
| US12383246B2 (en) | 2020-10-12 | 2025-08-12 | Abbott Cardiovascular Systems, Inc. | Vessel closure device with improved safety and tract hemostasis |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060058829A1 (en) * | 2003-03-19 | 2006-03-16 | Sampson Douglas C | Intragastric volume-occupying device |
| US7785291B2 (en) | 2005-03-01 | 2010-08-31 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
| US7699863B2 (en) * | 2005-03-01 | 2010-04-20 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
| US8185206B2 (en) * | 2006-05-17 | 2012-05-22 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
| WO2010101877A1 (en) * | 2009-03-03 | 2010-09-10 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
| US9937344B2 (en) * | 2009-09-21 | 2018-04-10 | Medtronic, Inc. | Waveforms for electrical stimulation therapy |
| US8647358B2 (en) | 2011-01-21 | 2014-02-11 | Obalon Therapeutics Inc. | Intragastric device |
| PT2665511T (en) * | 2011-01-21 | 2016-11-04 | Obalon Therapeutics Inc | Intragastric device |
| US8202291B1 (en) | 2011-01-21 | 2012-06-19 | Obalon Therapeutics, Inc. | Intragastric device |
| US8292911B2 (en) | 2011-01-21 | 2012-10-23 | Obalon Therapeutics, Inc. | Intragastric device |
| EP3077037B1 (en) | 2013-12-04 | 2021-11-17 | ReShape Lifesciences Inc. | System for locating intragastric devices |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| CN116370644A (en) | 2014-06-11 | 2023-07-04 | 麻省理工学院 | Residency structures and related methods |
| WO2016057716A1 (en) | 2014-10-09 | 2016-04-14 | Obalon Therapeutics, Inc. | Ultrasonic systems and methods for locating and /or characterizing intragastric devices |
| US9597507B2 (en) | 2014-10-31 | 2017-03-21 | Medtronic, Inc. | Paired stimulation pulses based on sensed compound action potential |
| CN118975972A (en) | 2015-10-23 | 2024-11-19 | 林德拉治疗公司 | Gastric retention system for sustained release of therapeutic agents and method of use thereof |
| US10335303B2 (en) | 2015-12-07 | 2019-07-02 | Obalon Therapeutics, Inc. | Intragastric device |
| JP7030052B2 (en) | 2015-12-08 | 2022-03-04 | リンドラ セラピューティクス, インコーポレイティド | Geometry for gastric retention system |
| US10350100B2 (en) | 2016-04-12 | 2019-07-16 | Obalon Therapeutics, Inc. | System for detecting an intragastric balloon |
| US12109305B2 (en) | 2016-05-27 | 2024-10-08 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| EP3518902A4 (en) | 2016-09-30 | 2020-07-08 | Lyndra, Inc. | STOMACH RESTORATION SYSTEMS FOR RETARD RELEASE OF ACTIVE SUBSTANCES |
| US10772752B2 (en) | 2016-11-04 | 2020-09-15 | Obalon Therapeutics, Inc. | Pressure control system for intragastric device |
| WO2018227147A1 (en) | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
| CA3070948A1 (en) | 2017-07-24 | 2019-01-31 | Obalon Therapeutics, Inc. | Systems and methods for locating and/or characterizing intragastric devices |
| US10918511B2 (en) | 2017-07-26 | 2021-02-16 | Verily Life Sciences Llc | Ingestible intragastric balloon |
| US11925660B2 (en) * | 2018-08-10 | 2024-03-12 | Simeon Investment, Inc. | Treatment for obesity with superabsorbent materials |
| US11918602B2 (en) * | 2018-08-10 | 2024-03-05 | Simeon Investment, Inc. | Methods for reducing cholesterol with superabsorbent materials |
| US12285738B2 (en) | 2018-08-10 | 2025-04-29 | Simeon Investment, Inc. | Modulation of glucose bioaccessibility with superabsorbent materials |
| US12144894B2 (en) * | 2020-07-29 | 2024-11-19 | The Secant Group, Llc | Shape-guided controlled release and retention with structures including crosslinked poly(glycerol sebacate) |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0103481A1 (en) * | 1982-09-14 | 1984-03-21 | Ainsworth Nominees Proprietary Limited | Treatment and reduction of obesity in humans |
| US5055306A (en) | 1987-10-22 | 1991-10-08 | Aps Research Limited | Sustained-release formulations |
| US5084061A (en) | 1987-09-25 | 1992-01-28 | Gau Fred C | Intragastric balloon with improved valve locating means |
| US5750585A (en) * | 1995-04-04 | 1998-05-12 | Purdue Research Foundation | Super absorbent hydrogel foams |
| US5780057A (en) | 1996-02-19 | 1998-07-14 | Jagotec Ag | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids |
| US6077540A (en) * | 1997-08-08 | 2000-06-20 | Bayer Corporation | Gelatin spray coating |
| US6271278B1 (en) * | 1997-05-13 | 2001-08-07 | Purdue Research Foundation | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
| US6326028B1 (en) * | 1997-10-31 | 2001-12-04 | Monsanto Company | Alginate and gellan gum as tablet coating |
| US6432448B1 (en) * | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| US6503264B1 (en) | 2000-03-03 | 2003-01-07 | Bioenterics Corporation | Endoscopic device for removing an intragastric balloon |
| US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| US6861072B1 (en) * | 1998-10-16 | 2005-03-01 | Sanofi-Synthelabo | Pharmaceutical composition with gastric residence and controlled release |
| US20070078476A1 (en) * | 2004-10-12 | 2007-04-05 | Hull Wendell C Sr | Overweight control apparatuses for insertion into the stomach |
| US20080107732A1 (en) * | 2004-03-25 | 2008-05-08 | Dharmadhikari Nitin Bhalachand | Gastric Retention System |
| US20080208240A1 (en) * | 2005-08-11 | 2008-08-28 | Stimplant Ltd. | Implantable Device For Obesity Prevention |
-
2005
- 2005-11-08 US US11/270,397 patent/US7674396B2/en not_active Expired - Fee Related
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0103481A1 (en) * | 1982-09-14 | 1984-03-21 | Ainsworth Nominees Proprietary Limited | Treatment and reduction of obesity in humans |
| US5084061A (en) | 1987-09-25 | 1992-01-28 | Gau Fred C | Intragastric balloon with improved valve locating means |
| US5055306A (en) | 1987-10-22 | 1991-10-08 | Aps Research Limited | Sustained-release formulations |
| US5750585A (en) * | 1995-04-04 | 1998-05-12 | Purdue Research Foundation | Super absorbent hydrogel foams |
| US5780057A (en) | 1996-02-19 | 1998-07-14 | Jagotec Ag | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids |
| US6271278B1 (en) * | 1997-05-13 | 2001-08-07 | Purdue Research Foundation | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
| US6077540A (en) * | 1997-08-08 | 2000-06-20 | Bayer Corporation | Gelatin spray coating |
| US6326028B1 (en) * | 1997-10-31 | 2001-12-04 | Monsanto Company | Alginate and gellan gum as tablet coating |
| US6861072B1 (en) * | 1998-10-16 | 2005-03-01 | Sanofi-Synthelabo | Pharmaceutical composition with gastric residence and controlled release |
| US6432448B1 (en) * | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| US6503264B1 (en) | 2000-03-03 | 2003-01-07 | Bioenterics Corporation | Endoscopic device for removing an intragastric balloon |
| US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| US20080107732A1 (en) * | 2004-03-25 | 2008-05-08 | Dharmadhikari Nitin Bhalachand | Gastric Retention System |
| US20070078476A1 (en) * | 2004-10-12 | 2007-04-05 | Hull Wendell C Sr | Overweight control apparatuses for insertion into the stomach |
| US20080208240A1 (en) * | 2005-08-11 | 2008-08-28 | Stimplant Ltd. | Implantable Device For Obesity Prevention |
Non-Patent Citations (2)
| Title |
|---|
| Silverman, R. The Organic Chemistry of Drug Design and Drug Action, Chapter 2 "Drug Discovery, Design, and Development", published 1992 by Academic Press, pp. 4-47. * |
| STN Database Descriptions, from 2006 Chemical Abstracts catalog, published 2006 by Chemical Abstracts Service, p. 52. * |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10874537B2 (en) | 2008-10-16 | 2020-12-29 | Obalon Therapeutics, Inc. | Intragastric volume-occupying device and method for fabricating same |
| US12102547B2 (en) | 2008-10-16 | 2024-10-01 | Reshape Lifesciences Inc. | Intragastric volume-occupying device and method for fabricating same |
| US12090075B2 (en) | 2008-10-16 | 2024-09-17 | Reshape Lifesciences Inc. | Intragastric device |
| US11219543B2 (en) | 2008-10-16 | 2022-01-11 | Reshape Lifesciences Inc. | Intragastric device |
| US11607329B2 (en) | 2010-06-13 | 2023-03-21 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US11135078B2 (en) | 2010-06-13 | 2021-10-05 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US11596538B2 (en) | 2010-06-13 | 2023-03-07 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10512557B2 (en) | 2010-06-13 | 2019-12-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US11351050B2 (en) | 2010-06-13 | 2022-06-07 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10413436B2 (en) | 2010-06-13 | 2019-09-17 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10610396B2 (en) | 2011-01-21 | 2020-04-07 | Obalon Therapeutics, Inc. | Intragastric device |
| US11737899B2 (en) | 2011-01-21 | 2023-08-29 | Reshape Lifesciences Inc. | Intragastric device |
| US12350179B2 (en) | 2011-01-21 | 2025-07-08 | Reshape Lifesciences Inc. | Intragastric device |
| US10463520B2 (en) | 2011-01-21 | 2019-11-05 | Obalon Therapeutics, Inc. | Intragastric device |
| US11974934B2 (en) | 2011-01-21 | 2024-05-07 | Reshape Lifesciences Inc. | Intragastric device |
| US11779482B2 (en) | 2011-01-21 | 2023-10-10 | Reshape Lifesciences Inc. | Intragastric device |
| US10507127B2 (en) * | 2012-06-07 | 2019-12-17 | Epitomee Medical Ltd. | Expandable device |
| US11712356B2 (en) | 2012-06-07 | 2023-08-01 | Epitomee Medical Ltd | Expanded device |
| US20150150701A1 (en) * | 2012-06-07 | 2015-06-04 | Tulip Medical Ltd. | Expanded device |
| US11129793B2 (en) | 2013-12-05 | 2021-09-28 | Epitomee Medical Ltd | Retentive devices and systems for in-situ release of pharmaceutical active agents |
| US20170172778A1 (en) * | 2015-12-16 | 2017-06-22 | Obalon Therapeutics, Inc. | Intragastric device with expandable portions |
| US10537453B2 (en) * | 2015-12-16 | 2020-01-21 | Obalon Therapeutics, Inc. | Intragastric device with expandable portions |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US12383246B2 (en) | 2020-10-12 | 2025-08-12 | Abbott Cardiovascular Systems, Inc. | Vessel closure device with improved safety and tract hemostasis |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070104754A1 (en) | 2007-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7674396B2 (en) | Method and system for treatment of eating disorders | |
| US7879355B2 (en) | Method and system for treatment of eating disorders | |
| US11786474B2 (en) | Device and method for reducing calorie intake | |
| US20130245663A1 (en) | Devices, Systems and Methods for Treatment of Eating Disorders | |
| EP1307218B1 (en) | Treatment of obesity | |
| US10548753B2 (en) | Passive caloric bypass device | |
| Loffredo et al. | Three Years Experience with the New Intragastric Balloon, and A Preoperative Test for Success witb Restrictive Surgery | |
| EP3329883B1 (en) | Intragastric device for treating obesity | |
| JP2001523491A (en) | Gastric cavity expander device and method | |
| US20100228349A1 (en) | Bulking of upper esophageal sphincter for treatment of obesity | |
| WO2011149888A2 (en) | Methods and devices for regulating the activation of ghrelin hormones within a stomach | |
| CN108852578A (en) | It is a kind of can natural degradation implantation material | |
| EP2066303B1 (en) | System for treatment of eating disorders | |
| US20110295179A1 (en) | Methods and devices for regulating the activation of ghrelin hormones within a stomach | |
| WO2008039193A2 (en) | Method and system for treatment of eating disorders | |
| EP1718279A2 (en) | Device and method for reducing calorie intake | |
| RU2306901C2 (en) | Method and device for curing morbid obesity | |
| Favretti et al. | The BioEnterics intragastric balloon for the nonsurgical treatment of obesity and morbid obesity | |
| CN109820628B (en) | Double weight-losing capsule for reducing stomach volume and heat | |
| Teixeira et al. | Obalon Intragastric Balloon System Overview | |
| Genco et al. | Endoscopic treatment: intragastric balloon | |
| Deitel | Surgical approaches to the management of obesity | |
| Dargent | First international new technologies and expert meeting | |
| Chung et al. | Bariatric Surgery: Choice of Operative Procedure | |
| JP2017176640A (en) | Gastric space filling device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: PLENSAT, LLC,TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STERLING, BERNHARD B.;MILLS, ALEXANER K.;REEL/FRAME:017268/0249 Effective date: 20051107 Owner name: PLENSAT, LLC, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STERLING, BERNHARD B.;MILLS, ALEXANER K.;REEL/FRAME:017268/0249 Effective date: 20051107 |
|
| AS | Assignment |
Owner name: PLENSAT, LLC,CALIFORNIA Free format text: CHANGE OF ASSIGNEE ADDRESS;ASSIGNOR:PLENSAT, LLC;REEL/FRAME:018209/0254 Effective date: 20060816 Owner name: PLENSAT, LLC, CALIFORNIA Free format text: CHANGE OF ASSIGNEE ADDRESS;ASSIGNOR:PLENSAT, LLC;REEL/FRAME:018209/0254 Effective date: 20060816 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
| FEPP | Fee payment procedure |
Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, SMALL ENTITY (ORIGINAL EVENT CODE: M2555) |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552) Year of fee payment: 8 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220309 |